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Abstract: The focus on nanotechnology in cancer treatment and diagnosis has intensified due 
to the serious side effects caused by anticancer agents as a result of their cytotoxic actions on 
normal cells. This nonspecific action of chemotherapy has awakened a need for formulations 
capable of definitive targeting with enhanced tumor-killing. Nanooncology, the application 
of nanobiotechnology to the management of cancer, is currently the most important area of 
nanomedicine. Currently several nanomaterial-based drug-delivery systems are in vogue and 
several others are in various stages of development. Tumor-targeted drug-delivery systems are 
envisioned as magic bullets for cancer therapy and several groups are working globally for 
development of robust systems.
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Introduction
Nanotechnology is the latest hype of modern technology and has applications in several 
human disease-related problems. Nanotechnology refers to the understanding and control 
of matter at dimensions between approximately 1 and 100 nanometers, where unique 
phenomena enable novel applications. Dimensions between approximately 1 and 100 
nanometers are known as the nanoscale. Unusual physical, chemical, and biological 
properties can emerge in materials at this scale and these properties may differ in 
important ways from the properties of bulk materials and single atoms or molecules. 
Nanotechnology has been applied in varied fields like electronics, energy, space, 
medicine, food, and chemical sensors and in molecular manufacturing.   Nanomedicine 
is a branch that focuses on application of nanotechnology in faster diagnosis, enhanced 
therapeutics, improved imaging, and prevention of various clinical conditions. In 
particular, it is used in drug delivery, diagnosis, imaging, and therapy. There are several 
nanomaterial-based agents under various stages of development with applications in 
medicine and some are in clinical use. With the changes in disease incidence, mortality, 
and treatment response for chronic ailments like cancer, neurodegenerative disorders, or 
metabolic syndrome, there is a need for development of newer technologies for early and 
rapid diagnosis and new safe drugs for treatment. Nanotechnology-based agents have 
given many promising leads in such areas. Among many areas, cancer nanotechnology 
or nanooncology has been a notable area of interest for several groups. Currently there 
are several nanomaterial-based agents for cancer therapy in the clinics and several others 
in varying stages of development. This review will discuss the diverse applications of 
nanotechnology, particularly in the field of cancer therapy.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Nanotechnology in medicine
A nanoparticle (NP) is defined as the smallest unit 
(10-9 meters) that can still behave as a whole entity in terms 
of properties and transport. NPs are particulate dispersions 
or solid particles ranging from 10 to 100 nm in size (in one 
dimension) and are being developed to: improve drug bio-
availability, abrogate treatment-induced drug resistance, and 
reduce nonspecific toxicity in the field of medicine. Several 
recent studies have shown that nanomaterials are able to cross 
biological membranes and access cells,   tissues, and organs 
that larger-sized particles normally cannot. Based on the 
chemical nature of the preparations, there are diverse types 
of nanoparticles that have been synthesized and evaluated. 
Nanomaterial-based agents used for drug   delivery include 
carbon NPs, dendrimers, ceramic NPs, chitosan NPs, 
liposomes, low-density lipoproteins, nanoemulsions, and 
nanospheres, etc.1 In all these types, drugs can be absorbed 
onto the surface, entrapped inside, or dissolved within the 
matrix of the NPs.
Recent advances in medicine and health care have greatly 
improved the life span of humans. This increase in life 
span also comes with an increased risk for several types of 
cancer, as cancer is considered as a disease of old age. It is 
also true that, during aging, individuals present with several 
comorbidities along with their diagnosis of cancer. Hence 
there is an increasing need to develop new agents for therapy 
of cancers that is effective and addresses such associated 
risks. Currently, chemotherapy using cytotoxic agents is the 
main stay for treatment of several malignancies.1 Besides, 
cytotoxic chemotherapy, antihormone therapy, molecular-
targeted therapies are also practiced, either single agent or in 
combination with conventional therapies. But several issues 
including costs and nontarget toxicity limit such combination 
treatments. Hence, there is a need to develop novel agents 
for treatment of cancers, which are less toxic, affordable, and 
provide better quality of life.
Limitations of current cancer  
treatment modalities
Currently available chemotherapy agents are time-tested, 
and confer good disease-free survival for a limited period 
of time. Nevertheless, nontarget tissue toxicity and drug 
resistance curtails the utility of these agents. Thus there 
is scope to develop newer agents or site-specific delivery 
systems to transfer these chemotherapeutic agents, which 
can annul the important obstacles of toxicity and drug 
resistance.
Nanoparticles as delivery vehicles
Nanoparticle-based drug-delivery systems have made a 
remarkable difference in site-specific release of chemo-
therapeutic agents, owing to their physical and chemical 
characteristics and biological attributes. Research in this 
exciting area has been happening for more than two decades, 
but only in the last decade were several of these formulations 
released in the market and are now routinely used in clinics. 
This type of research is very promising and the conglomera-
tion of expertise from a multidisciplinary team of polymer 
chemists, cancer biologists, and pharmacologists has seen 
several innovative agents become available.
Contributions from basic cancer biology 
for drug delivery
Research in the field of molecular oncology, which deals with 
basic disease mechanisms, has shown six important charac-
teristics of tumor cells, referred as the “hallmarks of cancer”.2 
Sustained angiogenesis is one characteristic, which indicates 
that tumors develop their own blood supply from the exist-
ing host vessels for nourishment. Several studies on tumor 
vasculature have shown them to possess structural anomalies 
that impede drug delivery. The tumor vasculature is known 
to possess poor architecture with an abnormal basement 
membrane and fissures between the endothelial cells due 
to an absent pericyte lining. This state of leaky vasculature 
accompanied by a poor lymphatic drainage system causes a 
differential interstitial pressure at the center of tumors than 
at the periphery. Due to this pressure difference, molecules 
ranging from approximately 10 nm to 100 nm, preferentially 
accumulate in the tumors and are retained longer, unlike the 
uncoated drugs, which are of much smaller size and cleared 
by the kidneys.3 This phenomenon is called the enhanced 
permeability and retention effect (EPR). A schematic repre-
sentation of leaky vasculature and EPR is shown in Figure 1. 
Studies have shown that the retention time of drugs packed in 
NPs is ten times higher than that of unpacked drugs, which 
eventually return to the vascular system.4 Hence, this EPR 
effect attributed to the leaky vasculature is considered as a 
boon for drug-delivery systems within the nanosize range. 
A schematic representation for passive targeting of NPs 
owing to EPR effect in tumors is shown in Figure 2.
Examples of nanomaterials used  
for drug delivery
There is considerable flexibility in the choice of raw 
materials and the methods of synthesis which can be 
adopted to fabricate nanoscale drug-delivery systems based International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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on their application. In this review we shall discuss different 
kinds of nanomaterial-based drug-delivery systems, with a 
focus on their components, applications, advantages, and 
limitations of the preparations.
Liposomes
Liposomes are self-assembled phospholipid membranes 
with an inner core where drugs can be entrapped. Liposomes 
are relatively stable, biodegradable, and do not elicit any 
immune response. They are efficient vehicles for targeted 
delivery of hydrophobic drugs. Liposomes are vesicular 
formulations of lipid bilayers prepared synthetically. 
The water-soluble drugs are present in aqueous compart-
ments while lipid-soluble drugs and amphiphilic drugs 
insert themselves in the phospholipid bilayer. Liposomes 
have been in vogue for varied applications such as DNA 
delivery in gene therapy and genetic engineering, drug 
delivery in nutrition and dietary supplements, or   cosmetics. 
  Liposomes may be synthesized in various sizes and shapes, 
however, nanoscale liposomes called nanosomes are of 
specific interest in targeting cancer. Such nanosomes are 
several nanometers in size and most commonly contain 
  anticancer drug(s).5,6 Since nanosomes are soluble in 
  aqueous solvents (like blood), they can carry hydrophilic as 
well as hydrophobic molecules, thus allowing administra-
tion of anticancer drugs that showed poor efficacy due to 
their limited solubility. A nanosome is essentially a vesicular 
lipid bilayer with the polar heads facing the solvent and 
the tail regions facing each other. The anticancer drug, if 
hydrophobic, can thus be contained in the tail region, and 
if hydrophilic, solubilized in the liposomal core. Surface 
modification of liposomes using polyethylene glycol (PEG), 
confers the liposomes stealth property, from being destroyed 
by the reticuloendothelial system. PEGylated (STEALTH) 
liposomal doxorubicin (Doxil®, Caelyx; Schering-Plough 
Pharmaceuticals, Kenilworth, NJ) was the first liposomal 
anticancer drug for the treatment of ovarian cancers to be 
approved by the US Food and Drug Administration. Several 
lipid-based formulations like liposomes have been synthe-
sized and characterized. We will review significant types 
for their novelty in composition, synthesis, size, shape, and 
applications. Newer generations of liposomes containing 
two anticancer agents within a single liposome are under 
development.
KEY
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Figure 1 The enhanced permeability and retention effect operating in tumor milieu permitting accumulation of nanometer-sized particles in cancer cells. Blood vessels in 
tumor tissue have defective architecture with gaps as large as 200–1000 nm allowing nanoparticles to extravasate and accumulate inside the tumor tissue. The retention 
time of drugs packed in nanoparticles is ten times higher than that of unpacked drugs, which eventually return to the vascular system. This phenomenon of permeability of 
molecules due to their size is a boon to cancer therapy and is known as the enhanced permeability and retention effect.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Lipid-based nanocapsules provide a novel approach for 
encapsulation of poorly soluble drugs like cisplatin or pacli-
taxel. Burger and colleagues developed a novel method for 
the efficient encapsulation of cisplatin in a lipid formulation 
based on repeated freezing and thawing of a concentrated 
solution of cisplatin in the presence of negatively charged 
phospholipids, namely dioleoyl-phosphatidylserine and 
  dioleoylphosphatidylcholine.7 This method generated nanocap-
sules, composed of small aggregates of cisplatin covered by a 
single lipid bilayer. These lipid preparations showed an excep-
tional drug-to-lipid ratio and when tested on ovarian cancer 
cells, showed 1000-fold higher cytotoxicity when compared to 
free drug. Though cisplatin is the drug of choice for treatment of 
ovarian neoplasms in particular, its utility is limited in the clini-
cal scenario because of its dose-limiting toxicity and acquired 
resistance. Hence it is imperative to develop delivery vehicles 
that can circumvent these issues. Several groups have attempted 
lipid-based nanoformulations for cisplatin delivery, but their 
application is limited due to cisplatin’s poor water and lipid 
solubility. This study by Burger et al is unique because it had 
addressed these issues with a basic freeze–thaw method for a 
nanoformulation, using simple phospholipids.7
Several research groups have used numerous combina-
tions of lipids to generate liposomes with ideal qualities. 
In one such attempt, researchers fabricated carboxylated 
hyperbranched polymeric liposomes that act on a pH-
dependent stimulus.8 Hyperbranched 3-methyl-glutarylated 
poly(glycidol) (HPG) polymers have been constructed with 
varying degrees of polymerization and a co-pH-sensitive 
stimulus that showed enhanced uptake of the NP due to the 
presence of fusogenic active membranes. Such liposomes were 
built on the idea that the presence of fusogenic membrane 
active proteins conjugated on polymers would be stable prior 
to lipid membrane fusion but will relieve its contents when 
brought in contact with endosomal or lysosomal compart-
ments within the cytosol. HPG polymers are similar to PEG 
chains except that such polymers bear carboxyl side groups 
and are complexly convoluted to give a three-dimensional 
(3D) spherical appearance rather than being linear. This 3D 
structure brings about steric hindrance that is required dur-
ing membrane fusion. Many of these polymers are surface-
conjugated with viral fusogenic peptides that add to their 
endocytic uptake by the target cell. This novel approach acts 
as a potent substitute to poly(ethylene glycol) that provides a 
Endothelial cells
Erythrocyte
Uncoated drug
Nanoparticle
Nontarget
cell toxicity
Target cell
killing Nontargeting/healthy cell
Uncoated drug
reflux
Nontargeting cell
Systemic toxicity
minimized
Passive targeting
100 nm–2 µm
leaky vasculature
Tumor cells
Figure 2 Passive targeting of nanoparticles to tumor cells according to tumor vasculature and size characteristics. Passive targeting of nanoparticles: nanoparticles (in yellow) 
concentrate to tumor sites taking advantage of leaky vasculature and diminished lymphatics. Tumor angiogenesis is torturous and aberrant with gap sizes of 100 nm–2 µm. 
Nanocarriers because of their small size can thus accumulate in tumor interstitium minimizing systemic toxicity and enhancing tumor cell killing. Free or uncoated anticancer 
drugs (blue) lack this advantage accounting for serious side effects due to extravasation to healthy cells and reflux at target sites. Yellow arrows indicate the extravasation 
of nanocarriers to the tumor site (indicated with thickened arrows, in addition, to represent higher biodistribution). Blue arrows indicate the extravasation of the uncoated 
drug to the nontargeting site rendering systemic toxicity, which is further thickened to symbolize higher concentration of the uncoated drug.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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3D arrangement to liposomes which emphasizes cell mem-
brane adhesion. Addition of fusogenic peptides like viral 
proteins further encourages effective target cell membrane 
fusion and eventually ensures endocytosis by target cells. 
Figure 3 depicts the performance and selective advantages 
of a stealth NP under in vivo systems.
Torchilin et al have reported enhanced efficacy of a tumor-
specific monoclonal antibody possessing nucleosome-restricted 
specificity and conjugated to PEGylated-doxorubicin-loaded 
liposomes.9 The actively targeted liposome bears monoclo-
nal antinuclear autoantibodies 2C5 that mediate cytotoxicity 
via antibody-dependent cell cytotoxicity (ADCC) and bind to 
tumor-specific surface-bound intact nucleosomes, stemmed 
from neighboring apoptotic tumor cells. A novelty in these tar-
geted liposomes, is that the tumor-recognizing antibody, 2C5, 
is derived with PEG and then was inserted to the liposomal 
corona. Modification of the liposomes using this method yielded 
a stoichiometry of approximately 70 antibody molecules on 
the liposome surface, conferring a strong antigen-antibody 
interaction, favoring the delivery of the therapeutic load in to 
the tumor cells. Nanosized liposomes have also been enriched 
to approach issues like multidrug resistance commonly 
observed in administration of free drugs. This occurs due 
to action of adenosine triphosphate (ATP)-efflux pumps 
activated via P-glycoproteins. A finding has reported suc-
cessful curtailment of cellular resistance and effective cell 
death by constructing a cationic liposome incorporated with 
doxorubicin and small-interfering RNA (siRNA) targeted 
to MRP1 and BCL2 mRNA. In this study a multifunctional 
cationic liposome has been fabricated which contains doxo-
rubicin and siRNA to the multidrug resistance protein MRP1 
and the antiapoptotic protein BCL2. Though the study had 
novelty in the synthesis of a system incorporating a thera-
peutic load and siRNA, had cell biology and in vitro studies, 
it did not show any data to substantiate the performance in 
vivo. Active targeting via novel stealth liposomes surface 
conjugated with fibronectin mimetics to specifically target 
tumor endothelial cells overexpressed with integrin alpha(5)
beta(1) family has also been attempted.10 Nanosomes have 
also been diversified for diagnosis and imaging apart from 
tumor therapy. A recent study has reported the development 
of paramagnetic and fluorescent liposomes actively targeted 
to tumor angiogenesis by conjugating integrin alpha(5)
beta(1) inhibitors.11
Opsonization by reticuloendothelial
system (RES)
Decreased blood circulation Elimination by RES
Liver
Spleen
Tumor interstitium
Passive targeting via stealth
Enhanced blood circulation
leading to hightened tumor
biodistribution
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Figure 3 Passive targeting of nanoparticles to tumor cells with stealth characteristics to evade rapid destruction by reticuloendothelial system and excretion. Passive targeting 
of PeGylated nanoparticles. Nanoparticles surface coated with poly(ethylene glycol) (PeG) are capable of evading reticuloendothelial system (ReS), thus delaying elimination 
to liver and spleen. Nanoparticles uncoated with PeG are easily recognized by the immune cells (phagocytes and monocytes) resulting in earlier elimination to liver and spleen. 
This results in decreased blood circulation and enhanced tumor localization of the anticancer nanovector.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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There are several dietary chemopreventive agents 
with potent bioactivity. Among such agents turmeric 
(Curcuma longa) is a crystalline compound commonly 
used in cuisine and for medicinal purposes in India. 
Curcumin (diferulomethane), a yellow pigment substance, 
is the active component of turmeric. Curcumin’s efficacy 
as a chemotherapeutic agent against several cancers of the 
stomach, prostate, breast, and lung has been documented.12–14 
The limitation in the clinical application of this agent is its 
poor bioavailability and hydrophobicity. Few research groups 
have started to fabricate nanomaterial-based delivery systems 
to circumvent such limitations. A recent study has reported 
the development of liposomal curcumin encompassing the 
anticancer curcumin within liposomal formulations.15 The 
efficacy of liposomal curcumin was examined on prostate 
cancer cell lines, LNCaP and C42B, in vitro. Treatment of 
cells with liposomal curcumin for a period of 24–48 hours 
resulted in suppression in cell proliferation to 70%–80% at a 
concentration of 5–10 µM on comparison of free or uncoated 
curcumin resulting in equal suppression at a concentration 
higher than 50 µM. In another study, liposome preparations 
of curcumin exhibited superior antiproliferative and apoptotic 
effects on six pancreatic cancer cells and also inhibited 
pancreatic tumor growth in mouse models.16 The in vivo 
studies also showed that liposomal curcumin preparations 
had better tumor inhibition capacity, and antiangiogenic 
effects compared with control vehicles, but this study did not 
include a group of animals treated with unpacked curcumin. 
The above-mentioned studies on curcumin indicate that 
nanomaterial preparations like liposomes are very useful in 
delivering such dietary compounds with poor solubility and 
hydrophobicity effectively to tumors.
While liposomes are associated with highlighted advantages 
over free drugs, they do exhibit serious toxicity like keratopa-
thy, mucositis, and myelosuppression not seen on administra-
tion of free anticancer drugs.17 Even though many liposomal 
formulations are clinically available, many of these prepara-
tions have problems with circulation time and have been shown 
to evoke immune responses. Han and colleagues suggested 
incorporating a comb-like polymer comprised of poly(methyl 
methacrylate) side chain to further improve circulation time.18 
Previous studies have also reported that the immune response 
is provoked due to polymers grafted on liposomal membrane 
and lipid dose.19,20 PEGylated liposomes elicit an anti-PEG 
IgM response in T cell-independent fashion while B cells 
may play a vital role in evoking immune response against 
empty PEGylated liposomes.21 This in vitro lympho-
cyte proliferation study published by Ishida showed that 
PEGylated liposomes elicited a T cell-independent manner. 
The ELISA-based assay performed on blood of nude mice 
pretreated with the PEGylated liposomes showed a strong 
anti-immunoglobulin M (anti-IgM) response after 5 days and 
a weak IgG response. Though the description of liposomes as 
phospholipid bilayers with drug loads according to the biologi-
cal resemblance seemed innocuous during the development, 
their performance on in vivo models have shown their limita-
tions, which couldn’t have been envisaged otherwise.
Besides liposomes, micelles are lipid-based preparations 
in the nanometer range that were found to be useful 
for drug-delivery applications. Micelles are colloidal 
aggregates of surfactants when dispersed in an aqueous 
solution. Micelles are different from liposomes in that they 
are monolayered and hence smaller in size. Micelles have 
recently been used for the delivery of drugs, foreign genes 
in gene-therapy procedures for cancer, and genetic disorders. 
Micellar formation occurs due to solvation at a threshold 
called critical micelle concentration (CMC),22 which is the 
concentration of the surfactants above which micelles are 
shaped. Micelles have recently been applied in oncology by 
designing nanoscale formulations that are capable of carrying 
anticancer agents and/or delivery of tumor-suppressive genes. 
Micelle   formation is affected by various factors such as 
concentration of the surfactant, temperature, pH, and ionic 
strength. Micelles show increased efficacy in targeting cancer 
as compared to free or uncoated drug by virtue of their EPR 
effect and reduced opsonization by surface conjugation 
with polymers. Because micelles are formed due to the 
monolayer association of surfactants, such molecules can 
only contain one kind of anticancer drug at a time, being 
hydrophobic. Micelles can thus be an advantage in cases of 
administration of one kind of hydrophobic anticancer drug 
such as the taxol family. Thus, micelles are yet another type of 
nanosomal preparation formed with a unilayer of a surfactant 
(ordinarily phospholipid) useful in gene therapy, and delivery 
of   hydrophobic drugs for cancer therapeutics.
In one of the earliest studies that reported the synthesis 
of PEG-phosphatidylethanolamine (PE) micelles contained 
the hydrophobic drug paclitaxel. Immunomicelles were 
designed with PEG-PE and possess stealth and tumor-
targeting properties. While PEG confers the stealth, the 
mAb incorporated in the corona of the micelle bestow 
its tumor-targeting property. In addition to this, the 
immunomicelle constructed was radiolabeled with 111In for 
quantifying the uptake and imaging the target site. These 
novel immunomicelles developed by Torchilin’s group had a 
unique tumor cell nucleosome-recognizing antibody, specific International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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to tumor cells.23 The lipid content of the micelle made it 
possible to accommodate sparsely soluble anticancer drugs 
like taxol. The immunomicelles, when tested on a mouse 
Lewis lung carcinoma model, showed improved tumor 
inhibition compared with free taxol. Immunomicelles that 
carry ligands against specific tumor antigens embedding the 
hydrophobic drug within its lipid bilayer can thus increase 
drug biodistribution. Owing to their poor solubility, drugs 
like taxol have a very low therapeutic index, but when 
delivered using such nanosystems, they demonstrate better 
efficacy and low nontarget toxicity.23,24 Micelles also show 
highlighted advantages over liposomes in several points. 
Firstly, micelles are smaller in size than the liposomes that 
ensure better uptake at tumor sites.23 Liposomes require 
optimum orientation for their successful localization 
within the tumor interstitium and take advantage of the 
leaky vasculature and diminished number of lymphatics 
whereas micelles show smooth and easier accumulation in 
the target site and do not have such constraints. Liposomes 
and micelles are synthesized from simple lipids and have 
their own advantages and limitations among the alternative 
preparations for drug-delivery polymer formulations being 
explored by several groups worldwide.
Synthetic copolymers for drug  
and siRNA nanoformulations
Polymeric formulations for drug delivery have been in vogue 
for a long time, but their potential in this arena has been 
hampered by stability and biocompatibility.   Nevertheless, 
several groups have developed unique polymer formula-
tions to address these issues. Polymer formulations of 
chemotherapeutic drugs have certain advantages such as 
increased solubility, prolonged duration of exposure, selec-
tive delivery of entrapped drug to the site of action, improved 
therapeutic index, and they potentially overcome resistance 
associated with the parent drug. Among the long list of poly-
meric formulations, several research groups have explored 
poly(cyanoacrylate) and poly(lactic acid)-based prepara-
tions extensively due to their improved   biocompatibility and 
  biodegradability. We will briefly discuss pertinent approaches 
using these formulations.
Amphiphilic copolymers are composed of hydrophilic 
and lipophilic moieties. Poly(alkyl cyanoacrylate) (PACA) 
NPs are amphiphilic copolymers that were first developed 25 
years ago by anionic polymerization of alkyl cyanoacrylate in 
the presence of dextran. PACA NPs are made of polymers that 
undergo in vivo degradation and have good biocompatibility. 
Various types of PACA NPs have been designed including 
nanospheres and oil- and water-containing nanocapsules. 
These NPs made possible the in vivo delivery of many dif-
ferent types of drugs including those presenting seriously 
challenging delivery problems.25
Ambruosi and colleagues investigated the biodistribution 
in the brain and body of tumor-bearing mice, 14C labeled, 
doxorubicin-loaded poly(butyl-2-cyanoacrylate) NPs and 
polysorbate-80 (P-80)-coated poly(butyl-2-cyanoacrylate) 
NPs.26 The study showed that the polysorbate coating of NPs 
prevented their uptake by the reticuloendothelial cells and the 
drug-loaded particles also showed uptake in the intracrani-
ally implanted glioblastoma cells, crossing the blood–brain 
barrier. Another study from the same group determined the 
influence of surfactants, polymer, and doxorubicin-loading 
on the antitumor effect of poly(butyl cyanoacrylate) NPs in 
a rat glioma model.27 The NPs were coated with different 
surfactants and injected intravenously on days 2, 5, and 
8 after intracranial implantation of glioblastoma to rats. 
Thirty-five percent of tumor-bearing animals treated with 
the poly(N-butyl cyanoacrylate) doxorubicin-loaded NPs 
coated with P-80 survived for over 180 days while animals 
treated with other NP preparations had lower survival times. 
The authors concluded that the difference in antitumoral 
efficacy could be attributed to the variable behavior of NP 
formulations, their surface charge, and their interaction with 
blood and the EPR effect.27
Brigger and colleagues evaluated the preclinical effi-
cacy of PEG-coated poly(hexadecyl)cyanoacrylate (PEG-
PHDCA) nanospheres loaded with doxorubicin, which as an 
unpacked drug, has poor distribution in the central nervous 
system.28 PEG-PHDCA nanospheres showed preferential 
accumulation in the intracranially implanted brain tumor 
cells. These nanospheres overcame multidrug resistance and 
performed better than the commercially available Caelyx 
(Janssen-Cilag Ltd, Buckinghamshire, UK), the stealth lipo-
somal preparation of doxorubicin. A later study by the same 
group, which used the same polyacrylate nanoparticulate 
preparations, interrogated the preclinical efficacy of the free 
and nanosphere-encapsulated   doxorubicin in 9 L gliosarcoma 
tumor models.29 The study showed that the doxorubicin-
loaded nanospheres accumulated more in lungs and spleen 
and has been attributed to binding of plasma proteins to 
the charged nanosphere surfaces. Despite this nonspecific 
accumulation of doxorubicin-loaded nanospheres, the 9 L 
tumor-bearing animals showed a higher maximum tolerated 
dose to the nanospheres as compared to the free drug.
In a recent study, curcumin-loaded poly(butyl cyano-
acrylate) NPs coated with chitosan were prepared by International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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emulsion polymerization.30 The particles thus prepared had 
spherical morphology and exhibited similar cytotoxicity to 
native curcumin against three human carcinoma cell lines. The 
authors also showed that the unloaded cyanoacrylate NPs did 
not show any toxicity to the cell lines. The study also showed 
that the curcumin-loaded cyanoacrylate particles decreased the 
levels of angiogenic stimulants, namely vascular endothelial 
growth factor and cyclooxygenase-2. Besides, the curcumin-
loaded particles could inhibit the hepatocellular xenografts 
in mice. A significant aspect in this study is that curcumin 
encapsulation in the poly(butyl cyanoacrylate) NPs showed 
an altered pharmacokinetic profile as compared to native 
curcumin. This study is important, since it is well known 
that native unpacked curcumin has good anticancer potency 
when tested on in vitro conditions, whereas it has reduced 
bioavailability under in vivo conditions. Thus NP prepara-
tion has been effective in delivering the drug at target site 
without compromise.
In a recent study, a naturally occurring apolipoprotein 
was used as a targeting ligand for poly(butyl cyanoacrylate) 
NPs loaded with curcumin.31 The ApoE3-labeled NPs showed 
preferential accumulation by receptor-mediated endocytosis 
and also inhibited beta-amyloid-induced cytotoxicity in 
neuroblastoma cells. These studies are important in that 
natural products with proven anticancer activity packed 
in a NP formulation have a better bioavailability profile 
and potential as useful agents for further research. This is 
because natural products like curcumin have the least or very 
low normal cell toxicity. Tamoxifen-loaded poly(MePEG-
cyanoacrylate-co-hexadecylcyanoacrylate) nanospheres were 
synthesized and characterized by Brigger and colleagues.32 
Tamoxifen encapsulated in nanospheres showed transcription 
inhibitory activity in ex vivo experiments.
Gemcitabine is a rapidly metabolized anticancer drug. To 
protect the drug, Stella and colleagues covalently coupled 
an acyl chain and this lipophilic derivative was   encapsulated 
using poly(H(2)NPEGCA-co-HDCA) nanospheres and 
nanocapsules.33 Their cytotoxicity was tested on two human 
cancer cell lines and compared with the cytotoxicity of gem-
citabine and free 4-(N)-stearoylgemcitabine.
Several research groups are actively working on NP-based 
systems for chemotherapeutic drug delivery to bring about 
effective tumor regression. Some groups are involved in 
development of cancer biotherapy involving activation of 
the cell’s own machinery to achieve regression. Among such 
biotherapy efforts, RNA interference (RNAi) is one such 
strategy. siRNAs are biomolecules that effectively   utilize the 
cell’s own enzymatic machinery to break down or regulate 
the mRNA levels of key proteins. Effective tumor regression 
can be achieved by sequencing siRNAs to silence genes 
or the proteins implicated in tumorigenesis. Though RNAi 
technology is just about a decade old, several clinical trials are 
in progress for assessing its therapeutic potential. The success 
of this technology is limited by several factors, which include 
stability of siRNA, inability to cross biological membranes, and 
off-target effects. Hence there are concerted efforts to develop 
a suitable carrier for effective, specific delivery of siRNA. In 
an interesting study by Toub and colleagues, siRNA against 
EWS-Fli1 fusion gene for oncogenic transcription factor, 
was encapsulated in a poly(isobutyl cyanoacrylate) aqueous 
core nanocapsule and delivered to NIH/3T3 cells ectopically 
expressing the Ewing’s sarcoma fusion gene.34 Studies of the 
intracellular penetration by confocal microscopy showed that 
nanocapsules improved the intracellular penetration of siRNA 
with mainly cytoplasmic localization. These biodegradable 
siRNA-loaded nanocapsules were then tested in vivo on 
EWS-Fli1-expressing mice tumor xenograft and were found 
to trigger a dose-dependent inhibition of tumor growth after 
intratumoral injection. A specific inhibition of EWS-Fli1 was 
also observed. This study showed that the alkylcyanoacrylate 
NPs could serve as versatile carriers of different therapeutic 
disposition inclusive of drugs and therapeutic biomolecules like 
the siRNA. A notable drawback in this study is the intratumoral 
administration of the nanoformulation. This approach does 
not allow for the evaluation of such nanomaterials with 
therapeutic biomolecules in the systemic circulation.
Current status of nanomaterial-based 
drug-delivery systems
Nanotherapeutics are rapidly progressing and are being 
implemented to solve several limitations of conventional 
drug-delivery systems such as nonspecific biodistribution 
and targeting, lack of water solubility, poor oral bioavail-
ability, and low therapeutic indices. Several stability and 
drug payload studies on the NP formulations have shown that 
they are highly stable with high carrier capacity, are feasible 
for incorporation of both hydrophilic and hydrophobic sub-
stances, and can be administered by various routes, including 
oral application and inhalation.35,36
NPs have been designed for optimal size and surface 
characteristics to increase their circulation time in the 
bloodstream and their biodistribution. They are also able to 
carry their loaded active drugs to cancer cells by selectively 
using the unique pathophysiology of tumors, such as their 
enhanced permeability and retention effect and the tumor 
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approved for treatment of a variety of chronic diseases includ-
ing cancer. Table 1 gives a list of such clinically approved NP 
systems and their indications. NP-based drugs like Emend®   
(Merck Sharp & Dohme Ltd, Herts, UK) and TriCor® (Abbott 
Laboratories, North Chicago, IL) have been approved for the 
suppression of chemotherapy-induced nausea and vomiting 
and to reduce cholesterol. In 1996, the first NP-based drug, 
DaunoXome® (Gilead Sciences, Cambridge, UK), was 
approved by the US Food and Drug Administration for the 
treatment of Kaposi’s sarcoma. Multifunctional and multi-
plex NPs are now being actively investigated and are on the 
horizon as the next generation of NPs for personalized and 
tailored cancer treatment.
Nanomaterial-based drug-delivery systems synthesized 
from any starting materials like the lipid-based liposomal 
or the cyanoacrylate-based formulations have been tested 
in several models and have been shown to be useful for 
drug delivery. A limited number of these preparations are 
also used in the clinics for treatment of malignant dis-
eases. Nevertheless, despite their acceptable therapeutic 
load delivery, these systems suffer from disadvantages like 
biocompatibility and lack of target specificity. The need for 
development of targeted drug delivery using nanoformula-
tions has gained importance and is now taking a lead role. 
Many targets are being discovered through the application 
of genomic and proteomic technologies. Thus there is 
plenty of room to improvise these systems to address the 
above-mentioned issues and several groups including ours are 
working to improve the targeting properties of NPs and for 
the   development of targeted therapeutics. In the following 
section we will discuss the current research in development 
of targeted drug-delivery systems.
Introduction to targeted  
drug delivery
A promising strategy to achieve direct drug delivery is the 
development of active targeting of cancer cells through 
interactions mediated by ligands such as antibodies, lectins, 
aptamers, folate, and peptides as presented with NPs. Active 
tumor-targeting of NPs may be achieved with either direct 
targeting or the pretargeting multistep method. In direct 
targeting, NPs could be covalently coupled with the ligand 
and the resulting drug carrier be administered at once. 
In the pretargeting approach, the therapeutic molecule is 
not coupled with the ligand and is administered after an 
appropriate delay following the targeting ligand. This delay 
allows time for the antibody to localize and concentrate in 
the tumor. Commonly, pretargeting protocol involves an 
avidin-biotin system or bispecific antibodies.
Models for targeted drug delivery
Anti-HeR2 antibody-labeled NPs
Antibody-labeled NP is one of the most coveted modes of 
active targeting of NPs. mAb is currently a solitary therapeutic 
option in clinics as a form of immunotherapy for cancer 
targeting of the aberrantly upregulated cell surface receptors 
pivotal in tumor cell proliferation, motility, and metastasis. 
Thus blocking the activity of the upregulated receptor by 
Table 1 Clinically approved nanoparticle systems and their indication
Compound Nature Trade name Indication Status Year of approval
Liposomal  
daunorubicin
Liposome-drug conjugate DaunoXome Kaposi’s sarcoma Approved 1996
Rapamycin Antibiotic Rapamune Antiproliferative agent  
in colorectal cancer
Approved 1999
Liposomal  
vincristine
Liposome-drug conjugate OncoTCS Non-Hodgkin’s lymphoma Approved 2004
Liposomal  
doxorubicin
Liposome-drug conjugate Myocet Metastatic breast cancer  
in combination with  
cyclophosphamide
Approved  
(europe)
2005
Stealth liposomal  
doxorubicin
Liposome-drug conjugate Doxil/Caelyx Kaposi’s sarcoma, refractory  
ovarian and breast cancer
Approved 2005
Albumin-paclitaxel Albumin-drug conjugate Abraxane/ABI-007 Metastatic breast cancer Approved 2005
Megesterol acetate Hormone Megace Breast and endometrial cancer Approved 2005
Fenofibrate Hypolipidemic agents TriCor Reduction of cholesterol Approved 2005
PeG-L-asparaginase PeG-enzyme conjugate Oncaspar Leukemia Approved 2006
Nanopaclitaxel Mitotic inhibitor Nanoxel Breast cancer Approved 2007
Aprepitant NK1 receptor antagonist emend Suppression of chemotherapy- 
induced nausea and vomiting
Approved 2008
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binding it with a ligand (such as mAb represented on the 
nanovector) would ensure arrest of the signaling pathway(s). 
mAb are thus useful in recognition of cell surface antigens 
commonly dysregulated in cancers, for instance RTKs like 
EGFR/HER2. HER2 is an oncogene and its upregulation is 
manifested in several malignancies such as breast, ovarian, 
endometrial, and stomach cancers and is thus a thoroughly 
studied model for cancer therapy. Figure 4 explains the concept 
of antibody-targeted drug delivery as a model for active 
targeting. In a study by Nobs and colleagues, two approaches 
were attempted for targeted delivery of biodegradable 
poly(lactic acid) NPs to tumor cells.37 Anti-HER2 mAbs 
(trastuzumab; Herceptin® [Roche Products Ltd, Herts, 
UK]) and anti-CD20 mAbs (rituximab; Mabthera® [Roche 
Products Ltd]) were used as targeting ligands. Two cell lines 
were used, SKOV-3 human ovarian cancer cells expressing 
HER2 antigen, and Daudi lymphoma cells, expressing CD20 
antigen. On each cell line, the antibody directed against the 
nonexpressed antigen served as isotype-matched irrelevant 
control Ig. In the direct approach, NPs exposing mAbs at 
their surface were incubated with the two tumor cell lines. In 
the pretargeting protocol, tumor cells were pretargeted with 
biotinylated mAbs before the administration of avidin-labeled 
NPs. The cell interactions of  fluorescence-labeled NPs were 
measured by flow cytometry. The analysis showed that the 
targeted NPs accumulated in antigen-positive cells compared 
to nontargeted NPs.
Park and colleagues studied the pharmacokinetics 
and therapeutic efficacy of anti-HER2 immunoliposomes 
containing doxorubicin in animal models and showed that 
anti-HER2 immunoliposome-doxorubicin showed superior 
therapeutic benefits compared with combinations consisting 
of free Herceptin MAb plus free doxorubicin or free MAb 
plus liposomal doxorubicin.38 This study concluded that 
anti-HER2 immunoliposomes produced enhanced antitumor 
efficacy via targeted delivery.
Sun and colleagues synthesized poly(d,l-lactide-co-
glycolide)/montmorillonite (PLGA/MMT) NPs, which were 
decorated with HER2 antibody trastuzumab for targeted 
breast cancer chemotherapy with paclitaxel as a model anti-
cancer drug.39 Therapeutic studies using these NPs showed 
that the efficacy of the drug formulated in the NPs with 
surface decoration could be 12.74 times higher than that of 
the bare NPs and 13.11 times higher than taxol.
Gold–gold sulfide NPs when exposed to a pulsed near-
infrared resonant laser exhibit photoluminescence that can be 
utilized to visualize cancerous cells in vitro. When these NPs 
are conjugated with anti-HER2 antibodies there is a specific 
binding to SK-B3 breast cancer cells where HER2 receptor is 
overexpressed enabling precise imaging of the cancerous 
cells. When a higher excitation power was employed, thermal 
damage leading to cancer cell death was also observed.40
Apolipoprotein-labeled NPs
Apolipoproteins are carrier proteins that combine with lipids 
to form lipoprotein particles, that have hydrophobic ligands 
at the core and hydrophilic side chains made of amino acids. 
These lipoproteins are metabolized in liver and muscles 
through receptor-mediated endocytocis, recognized by the 
apoproteins in the complex. Thus apoproteins give an address 
for the lipoprotein to be taken up by specific receptors. The fact 
that apoproteins act as homing ligands prompted researchers 
to use that as a targeting label for NPs. Recently lipoproteins 
have come to the attention of oncologists with the realization 
that high-density lipoproteins (HDL) show increased uptake by 
tumor cells and in turn Effect cell proliferation. This is made 
possible as a consequence of the overexpression of the HDL 
receptor, scavenger receptor B1 (SR-B1).41 The receptor has 
been shown to be expressed in normal cells like that of liver 
cells, but reports have indicated gross upregulation of SR-B1 in 
tumor cells to concentrate HDL required for active cellular 
proliferation involving the STAT3 and FAK pathways.
Efforts have thus been made in the synthesis of targeted 
HDL NPs that can betray a tumor cell in uptake of HDL, thus 
loading the anticancer agent driving the tumor mass to direct 
cell killing. A group of scientists has reported an elaborate 
and unprecedented study on delivering siRNA tagged with 
synthetic reconstituted HDL (rHDL) NPs.41 The study was 
initiated with synthesis of siRNA surface tagged with HDL 
molecules and their characterization using transmission 
electron microscopy followed by in vitro studies on human 
cancer cell lines. In vitro cell line studies showed effective 
silencing of the target mRNAs. The rHDL loaded with the 
siRNAs was also tested and found to be effective on nude 
mice bearing ovarian xenografts.
Peptide-labeled NPs
Peptide labeling of NPs is steadily gaining importance in 
  cancer research. It can be employed to target drug conjugated 
NPs into specific cancer cells as they can be based on ligands 
associated with receptors on specific cells/organs/tumor 
cells themselves or tumor-support structures such as stroma 
or neovasculature. Peptides can also be used as structural 
building blocks of the NPs themselves. Peptide-labeled NPs 
can be used in the imaging of tumor cells and tumor   tissue. 
Fluorescent silica NPs (FSiNPs) coupled with a molecular International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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recognition element allows for effective in vitro and ex 
vivo imaging of tumor cells and tissues. A study reported 
the targeting and imaging of MDA-MB-231 human breast 
cancer cells using arginine-glycine-aspartic acid (RGD) 
peptide-labeled FSiNPs; the FSiNPs exhibited high target 
binding to alpha(5)beta(3) integrin receptor (ABIR)-positive 
MDA-MB-231 breast cancer cells in vitro.42 High integrin 
alpha(5)beta(3) expression level of the MDA-MB-231 tumors 
was clearly visible due to the special targeting effects of the 
RGD peptide-labeled FSiNPs.
Active targeting
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in dual manner -1-
at endothelial cell
2nd tumor direct targeting
Endosomal vesicle
pH-sensitized
anticancer agents in
cytosol that
transport to
nucleus TSA ligand
Tumor specific antigen (TSA)
Endothelial cell
Malignant cell
DNA fragementation
by anticancer drugs
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Figure 4 Active targeting of nanoparticles to tumor cells according to the presence of tumor-seeking addresses on nanoparticle surface promoting tumor residence. Active 
nanoparticle targeting: the nanoparticle is surface tagged with a certain ligand against a tumor-specific antigen. This enables direct targeting to target site. The model here 
discusses dual targeting effected in a synergistic fashion: targeting endothelial cell receptors (vascular cellular adhesion molecules, vascular endothelial growth factor, etc) such 
as angiogenesis antagonists and monoclonal antibodies against typical tumor signatures such as endothelial growth factor receptors, HeR2, which result in tumor cell apoptosis. 
endothelial cell targeting curbs angiogenesis of tumor interstitium preventing oxygen supply and nutrients while tumor targeting causes direct cell killing as the nanoparticle 
encapsulating the anticancer drug is taken up by the cell. (1) The nanoparticle is targeted against endothelial cell receptor and against a tumor antigen. (2) The nanoparticle 
is taken up by the tumor cell via endocytosis wherein nanocarrier vesicles formed release the contents in a pH-dependent manner. The anticancer drug(s) embedded in the 
nanovector is(are) released and translocated to the nucleus. (3) Action of anticancer drug results in DNA fragmentation that finally leads to (4) programmed cell death.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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Peptide-labeled NPs may also be used for targeted gene 
silencing. A study shows that RGD-CH-NP is a novel and 
highly selective delivery system for siRNA with the potential 
for broad applications in human disease.43 RGD peptide con-
jugated with chitosan by thiolation reaction was confirmed 
by proton-nuclear magnetic resonance (H-NMR). Binding 
of RGD-CH-NP with alpha(5)beta(3) integrin was examined 
by flow cytometry and fluorescence microscopy. Antitumor 
efficacy was examined in orthotopic mouse models of ovarian 
carcinoma. This approach resulted in significant inhibition 
of tumor growth compared with controls.
Aptamer-labeled NPs
Aptamers are DNA or RNA oligonucleotides that, through 
intramolecular interactions, fold into unique tertiary confor-
mations capable of binding to target proteins with high affin-
ity and specificity. This property makes them an attractive 
class of targeting molecules as they are also nonimmunogenic 
and exhibit remarkable stability and are often referred as 
chemical antibodies. Docetaxel (Dtxl)-encapsulated NP, 
with PLGA-b-PEG copolymer and surface fluoropyrimidine 
RNA aptamers, has been reported to recognize the extracel-
lular domain of prostate-specific antigen (PSMA) which is 
a well recognized antigen on the surface of prostate cancer 
cells. They bind and are taken up by the cells resulting in a 
significantly enhanced in vitro cellular toxicity as compared 
with nontargeted NP lacking PSMA, which demonstrates its 
therapeutic potential.44
Folate-linked NPs
Folic acid, a member of the B complex group of vitamins, is 
an important co-factor in one-carbon transfer reactions for 
biosynthesis of nucleotides and plays a key role in DNA and 
RNA synthesis, epigenetic processes, cellular proliferation, 
and survival. Three distinct transporters mediate cellular 
folate uptake. Among them, the folate transporter named 
as the folate receptor (FR), often referred to as the high 
affinity folate-binding protein, is a cell surface glycosyl-
phophatidylinositol (GPI)-anchored glycopeptide that 
characteristically binds folic acid and transports it by a 
nonclassical endocytic mechanism.45–47 A wide range of 
chemical conjugates of folic acid, antifolate drugs, and 
immunological agents have been used for developing 
therapeutic and imaging agents for various diseases. Studies 
have shown a significant correlation between FR alpha 
expression and the grade and differentiation status of the 
tumor, thus poorly differentiated and aggressive tumors 
express high levels of FR alpha.48
Folic acid is known to mediate intracellular NP uptake.49 
Folic acid is coupled with human serum albumin (HSA) NPs 
through carbodiimide reaction resulting in the formation 
of HSA-NPs spheres. The cellular binding and uptake was 
studied in normal foreskin fibroblasts (HFF), human neuro-
blastoma cells UKF-NB3, and in rat glioblastoma cell lines. 
An increased NP uptake was observed in cancer cells, but 
not in normal HFFs. This suggests its application in targeted 
tumor drug delivery.
Folate-linked NPs can also be used in tumor imaging 
and radiotherapy. In a recent study, folate-conjugated shell 
cross-linked NPs (SCKs) were functionalized with folate, 
fluorescein thiosemicarbazide (FTSC), and TETA.50 SCKs 
were obtained by cross-linking the shell of micelles obtained 
from amphiphilic diblock copolymers. It was investigated on 
KB cells and evaluated in athymic mice bearing small-size 
KB cell xenografts. The specific interaction of FTSC-SCK-
folate with the FR in vitro was confirmed. The evaluated64 
Cu-labeled SCKs exhibited long circulation in blood and 
were able to passively accumulate in tumors.
In case of cancers like colorectal carcinoma, where early 
detection can significantly improve mortality, an alginate-
complexed folate chitosan NP has been reported for photo-
dynamic detection. These NPs are readily engulfed by the 
cancer cells through folate receptor-mediated endocytosis. 
When they are loaded with 5-aminolevulinic acid (5-ALA) 
an improved release in the cellular lysosome was observed 
hinting at an excellent vector for colorectal-specific delivery 
of 5-ALA for fluorescent endoscopic detection.51
Folate-conjugated liposomes showed minimal nonspecific 
adsorption to serum proteins. Folate-PEG-liposome loaded 
with doxorubicin showed a 45-fold higher uptake in FR-rich 
KB cells compared to nontargeted liposomal-doxorubicin 
and 86-fold greater cytotoxicity. In mice bearing KB cell 
tumor xenografts, treatment with folate-targeted liposomal 
doxorubicin produced a 31% inhibition of tumor growth.52 
Another study using a multidrug-resistant M109R cell line 
overexpressing FR showed that the liposomal doxorubicin 
was taken up despite a functional drug efflux pump operating 
in the cells. This preparation had a 10-fold higher cytotoxic-
ity compared with control groups treated with nontargeted 
liposomes. Magnetic resonance imaging of mice bearing 
subcutaneous KB tumors showed that superparamagnetic 
iron oxide (SPIO) NPs were rapidly internalized in vivo by 
the tumor cells only when conjugated with folate.53,54
Tumor-targeted drug delivery systems are currently 
envisioned as magic bullets for cancer therapy and several 
groups are working globally for development of robust International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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systems addressing issues of specificity. A summary of a 
few important nanovector prototypes against typical tumor 
signatures is presented in Table 2.
Concept of multifunctional NPs
Nanoscale formulations for oncology have overcome the 
demerits associated with chemotherapeutic pharmaceuti-
cals such as specificity, toxicity, biodistribution to target 
site, elimination, and excretion. NPs are thus biodegradable 
materials that contain the anticancer agent within it. Their 
nanometer sizes enable efficient uptake at the tumor site by 
their enhanced permeability and retention effect. We sug-
gest a model for multifunctional NPs (Figure 5) that acts as 
a drug-delivery system as well as a diagnostic agent. With 
the concept of combination chemotherapy in practice, it is 
useful to deliver two different drugs of varying mechanisms 
of action in a single delivery vehicle. With this objective, 
the system could be designed to epitomize two anticancer 
drugs, drug 1 and drug 2, that are separated from each other 
via an emulsion column. Specifically, the anticancer agents 
are dissolved in separate matrices based on their solubility, 
whether lipophillic or hydrophilic. In addition, the model illus-
trates a stimulus-dependent release of the   pharmaceuticals. 
This is based on the concept that chemotherapeutic agents 
administered as prodrug only get metabolized into active 
form under suitable conditions, ideally present in the tumor 
interstitium. Thus the stimuli (such as oxygen pressure or 
pH) acts as a catalyst to cause the release of anticancer 
agent(s) particularly at the target site. On the exterior, the 
presence of a cell-penetrating peptide facilitates the cel-
lular entry of the nanomaterial. When a nanomaterial has 
the above-mentioned components, the targeting to tumor 
site is passive, while engineering ligands to tumor specific 
antigens would ensure more specific uptake to the tumor 
site, a phenomenon known as active targeting. In our model, 
we suggest dual targeting: one against the endothelial cell 
receptor and a second against the tumor marker. Endothelial 
cell targeting is a novel strategy to curb angiogenesis by 
sequestering receptors such as vascular cellular adhesion 
molecules, selectins, and vascular endothelial growth factor 
receptors that have been documented to be associated with 
tumor angiogenesis. In addition, antiangiogenic therapy-
enabled tumor killing has been conceived through several 
pharmacologic means. In this regard, developing agents that 
antagonize the angiogenic property of endothelial cells would 
enable reduced tumor growth by strategically cutting oxy-
gen and nutrient supply to the tumor interstitium.62 A study 
conducted by Jain reported that herceptin, the mAb against 
the cell surface receptor HER2, has antiangiogenic proper-
ties by normalizing the tumor vasculature in a mice model.63 
It is known that malignancies arise due to gross mutations 
attributable to upregulation of certain proteins that become 
the signatures of various cancers (these include HER2, PSA, 
EGFR). Monoclonal antibodies targeted against these tumor 
markers enable direct tumor targeting to tumor site leaving 
the normal cells unharmed, thus significantly reducing cyto-
toxicity. The strategy is to cut oxygen and nutrient supply to 
the tumor cells. A polymer like PEG is included to ensure 
Table 2 Important nanovector paradigms against typical tumor signatures
Target Animal model Nanoparticle used Hallmark  
targeted
Target ligand Reference
veGFR-2 BALB/c (4T1 xenografts) Boronated dendrimers Angiogenesis veGF analogue Backer et al55
veGF Nude mice (K1735-M2  
melanoma and CT-26 xenografts)
Dextran magnetic  
Nanoparticles conjugated  
with 90Y-anti-veGF mAb
Angiogenesis anti-veGF mAb Li et al56
αvβ3 Nude mice  
(M-21 L melanoma xenografts)
Cationic nanoparticles  
conjugated to integrin  
αvβ3–targeting ligand
Angiogenesis RGD mimetics Hood et al57
vCAM-1 Nude mice (CoLo 677 xenografts) vCAM-1 targeted  
immunoliposomes
Angiogenesis anti-vCAM mAb Gosk et al58
HeR-2 Nude mice  
(BT-474, MCF-7 xenografts)
Anti-HeR-2 Fab’ conjugated  
PeGylated immunoliposomes
Uncontrolled  
cell proliferation
Trastuzumab mAb,  
anti-HeR-2 Fab’ 
Kirpotin et al59
Transferrin  
receptors
NMRI Mice (HT-29 xenografts) Transferrin-modified  
nanoparticles  
containing DNAzymes
Uncontrolled  
cell proliferation
Transferrin  
Analog
Pun et al60
Folate receptor BALB/c mice J6456-FR xenografts Folate-targeted liposomes Uncontrolled  
cell proliferation
Folate Shmeeda  
et al61
Abbreviations: veGFR-2, vascular endothelial growth factor receptor-2; veGF, vascular endothelial growth factor; αvβ3, alpha5 beta 3 integrin; vCAM-1, vascular cell 
adhesion molecule 1; HeR-2, human epidermal growth factor receptor-2; mAb, monoclonal antibody; RGD, arginine, glycine, aspartate; Fab, fragment antigen-binding.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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stealth from the reticuloendothelial system so as to enhance 
bioavailability of the NP. For diagnostic purposes, an image 
contrast agent may be added to aid in magnetic resonance 
imaging. NPs engineered for diagnosis would enable early 
detection of tumor. This would also facilitate timely treatment 
of the tumor tentatively prior to metastasis.
Multifunctional magnetic NPs  
for cancer treatment
Hyperthermia offers an attractive approach for the treatment 
of cancer because it is associated with fewer side effects in 
comparison to chemo- and radiotherapy, and it can be used 
concomitantly with conventional modalities. Various clinical 
trials have demonstrated the efficacy of such combinations. 
The first use of magnetic NPs for hyperthermia was 
reported by Gilchrist in 1957.64 Although several potential 
hyperthermic particles such as silver, lanthanum, and 
zinc NPs are available, the thermal activation properties 
of gold NPs, magnetic NPs, and carbon nanotubes have 
been extensively characterized preclinically and they are 
furthest along in potential translation to clinical biomedical 
applications.65
Thermotherapy is most efficient for superficial cancers 
in the form of three modes: local, regional, and whole-body 
hyperthermia. Local and regional application of hyperthermia 
can be administered using heat-delivery systems that can dis-
sipate the dose of applied heat at the focused area of   cancer.66 
Radiofrequency ablation is the most commonly used type of 
local hyperthermia. In this technique, short duration high-
energy radio waves are concentrated at the site of the tumor 
with the aid of a thin needle-like probe via ultrasound guidance 
capable of emanating high-frequency current resulting in the 
heating of malignant cells in a minimally invasive fashion with-
out damaging adjacent vital structures.67   Three-dimensional 
phantom models have been developed to mimic tissues. 
Merkle and colleagues investigated the changes in heat 
deposition during RF ablation in the presence of SPIO NPs 
and reported that the temperature along the RF electrode 
track significantly increased because of the iron content in 
the polyacrylamide phantom; however, the use of SPIO at 
physiologic concentrations in rabbit models did not yield 
significant difference in coagulation diameter.68
Augmenting thermal therapy with magnetic NPs
Thermal therapy can be combined with newer more targeted 
strategies of tackling cancerous mass, such as nanotechnology 
or radiotherapy. Magnetic NPs have been studied for their 
tremendous potential in the diagnosis and treatment of cancer 
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Figure 5 A model for multifunctional nanoparticle with desired characteristics possessing multiple drugs, dual tumor-targeting ligands, cell-penetrating peptide, and imaging agents.International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
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and are being increasingly used for clinical applications such 
as drug delivery, magnetic resonance imaging and magnetic 
fluid hyperthermia. The concept of using magnetic NPs for 
drug delivery was proposed by Widder and Senyi in 1978.69 
All magnetic NPs used so far in vivo are composed of the 
iron oxides magnetite (Fe3O4) and maghemite (γ-Fe2O3) due 
to their low toxicity and biocompatibilty.70 Ferrite NPs are the 
most sought after, attributable to their physical and chemical 
properties that are best suited for hyperthermic applications. 
Two key issues dominate the magnetic properties of NPs: 
finite-size effects and surface effects which give rise to various 
special features. Finite-size effects result, for example, from 
the quantum confinement of the electrons, whereas typical 
surface effects are related to the symmetry breaking of the 
crystal structure at the boundary of each particle. Hence, for 
hyperthermia treatment, particles below 50 nm in diameter 
produce the maximum specific absorption rate.71 Iron oxide 
particles with diameters below 30–40 nm are of particular 
interest because they exhibit superparamagnetic behavior ie, 
once the magnetic field is removed, they do not retain any 
magnetization.
Heating cancer with magnetic NPs
Magnetic NPs can be used as heat-generating systems for 
therapeutic applications since they generate sufficient heat 
energy when exposed to an alternating magnetic field (AMF). 
These nanometric systems act like a single magnetic domain 
and hence exhibit the properties of a simple magnetic dipole.64 
Ivkov et al reported the feasibility of applying high-amplitude 
AMF to treat cancer tissue with embedded magnetic NPs 
in 39 female BALB/c athymic nude mice and observed no 
adverse effects in mice exposed to AMF amplitudes of #700 
Oe but mice exposed to AMF amplitudes in excess of 950 
Oe experienced morbidity and injury.72
Preclinical studies on various types of cancer using 
magnetic hyperthermia have been reported to have promis-
ing tumor responses in mouse models. These studies have 
been pursued independently by different research teams 
for breast, prostate, and brain tumor models. Clinical trials 
were conducted in Germany in 59 patients with recurrent 
glioblastoma multiforme who underwent a combination of 
intratumoral thermotherapy with low dose radiotherapy of 
30 Gy. The thermotherapy was performed using AMF and 
SPIOs as energy transducer. The results of the study reported 
a median overall survival of 13.4 months in 59 patients 
compared to 6.2 months reported from another study using 
temozolomide as the current standard in the treatment of 
primary glioblastoma.73
Active targeting of magnetic NPs
Magnetic targeting can be enabled by magnetoliposomes 
or magnetic polymer particles which can carry active drug 
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molecules that can be concentrated at a defined target site by 
local application of an external magnetic field. This can be 
enabled by surface modification of magnetic NPs where the 
NPs are conjugated with ligands against suitable molecules 
overexpressed in tumors. Occhipinti and colleagues syn-
thesized trastuzumab-functionalized PEGylated iron oxide 
NPs as a model to study the interaction between an mAB 
nanoconjugate and its receptor (HER2) and have docu-
mented the utility of magnetic NPs in designing and testing 
novel hybrid targeted nanovectors preventively providing 
a chance to reduce side effects like nonspecific uptake 
by normal   tissues.74 Natarajan and colleagues developed 
multifunctional radioimmunonanoparticles (RINPs) using 
recombinant antibody fragments, di-scFv-c, for the imag-
ing and therapy of anti-MUC-1-expressing tumors. RINP 
binding to tumor cells was found to be time-dependent 
and in vivo uptake was confirmed by pharmacokinetic 
and whole-body autoradiography in breast cancer mice 
models.75
Magnetic NPs have enormous theranostic application 
due to their unique and multifunctional properties. Recent 
advances in materials science allow control of the shape, 
size, and properties of magnetic NPs with limited toxicity 
and biodegradability. The challenge lies in designing the 
“  perfect” magnetic NPs combining the different functional-
ities for greater specificity towards targeted tissues and longer 
retention time. Such advancements could pave the way for 
an effective clinical practice.
Conclusion
Nanotechnology is the manipulation of materials to nanome-
ter scale. The use of nanotechnology has already flourished 
in various fields such as information and   communication. 
Nanomedicine is a subdiscipline that focuses the advan-
tages of nanotechnology on health care. NP-based drug-
delivery systems could be synthesized from a wide panel 
of startup materials, thus there is plenty of room for 
innovation in chemical synthesis. The chemist involved 
in such processes should consult a biologist to learn the 
application of the materials in medicine and biology, the 
therapeutic load it can carry, robust laboratory methodology 
to test the efficacy, target specificity, and most importantly, 
the biological fate of the materials. It is necessary that both 
the chemist and biologist discuss the material synthesized for 
human application with a pharmacologist, the stability of the 
systems in biological fluids, and efficacy as compared with 
conventional methods. Thus the emerging field of nanoon-
cology calls for an interplay of expertise from several basic 
science and clinical departments with the need for testing 
the nanomaterial-based agents for drug delivery in phase 
trials in recognized medical centers with good ethical prac-
tices. A newly developed nanomaterial-based drug-delivery 
system has to perform at various levels; only then can it 
reach its final destination of application to alleviate human 
ailments. The growing list of approved NPs in medicine 
(Figure 6) and newer agents in the pipeline present great 
hopes for our future.
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